• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Bexion Pharmaceuticals

Monday, June 03, 2024
CP
Oncology
Bexion Pharmaceuticals is a biotechnology company developing biologics targeting sphingolipid metabolism for the treatment of solid tumors and chemotherapy-induced peripheral neuropathy (CIPN). Lead asset BXQ-350 modulates sphingolipid metabolism, increasing the ratio of certain ceramides to S1P in dysregulated cells, allowing for programmed cell death, reduced proliferation, and immune stimulation.
Bexion Pharmaceuticals
Company Website: https://www.bexionpharma.com/
Lead Product in Development: BXQ-350 - An innovative asset with potential for multiple indications. BXQ-350 is a lipid nanovesicle of Saposin C, a protein that activates sphingolipid metabolism to increase ceramides and reduce S1P. Ceramides and S1P are key therapeutic targets in CRC that impact survival.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 1

Company HQ City

Covington

Company HQ State

KY

Company HQ Country

United States

CEO/Top Company Official

Scott Shively - CEO

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS